Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Atezolizumab + Carboplatin + Etoposide
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Atezolizumab Tecentriq RG7446|MPDL3280A Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov).
Carboplatin Paraplatin CBDCA Chemotherapy - Platinum 7 Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).
Etoposide Vepesid EPEG|Eposin|VP-16|VP-16-213 TOPO2 inhibitor 5 Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06362252 Phase Ib/II Atezolizumab + Carboplatin + Ifinatamab deruxtecan Atezolizumab + Carboplatin + Etoposide Atezolizumab + Ifinatamab deruxtecan A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) Recruiting USA | FRA | ESP 1
NCT02748889 Phase Ib/II Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer Terminated USA 0
NCT05142696 Phase I Atezolizumab + Carboplatin + Etoposide + lutetium Lu 177 dotatate Atezolizumab + Carboplatin + Etoposide A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab Recruiting USA | GBR | FRA | ESP | DEU 0
NCT04487756 Phase Ib/II Atezolizumab + Carboplatin + Etoposide Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (VENEZO-LUNG) Active, not recruiting ESP 0
NCT05091567 Phase III Atezolizumab + Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide + Lurbinectedin A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte) Active, not recruiting USA | TUR | POL | ITA | HUN | GRC | GBR | ESP | DEU | BEL 3
NCT04610684 Phase II Atezolizumab Atezolizumab + Carboplatin + Etoposide Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases Terminated USA 0
NCT05224141 Phase III Carboplatin + Etoposide + MK-7684A Cisplatin + Etoposide + MK-7684A Atezolizumab + Cisplatin + Etoposide Atezolizumab + Carboplatin + Etoposide Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) Active, not recruiting USA | TUR | ROU | POL | NLD | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | AUT | AUS | ARG 5
NCT05468489 Phase III Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide + Serplulimab To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC Recruiting USA 0
NCT03041311 Phase II Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) Terminated USA | LVA | FRA | EST | ESP | BGR 1
NCT06110572 Phase Ib/II Atezolizumab + Carboplatin + Etoposide Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TESSERACT) Recruiting USA 0
NCT04923776 Phase II Atezolizumab + Carboplatin + Etoposide Liver Directed RT + Chemo-immunotherapy for ES-SCLC Recruiting USA 0
NCT04256421 Phase III Atezolizumab + Carboplatin + Etoposide + Tiragolumab Atezolizumab + Carboplatin + Etoposide A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02) Active, not recruiting USA | TUR | POL | NZL | NLD | ITA | HUN | GRC | GBR | ESP | DEU | CZE | CHE | BRA | BEL | AUT | AUS 6
NCT03811002 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer Active, not recruiting USA 1
NCT05312671 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Recruiting USA 0
NCT05058651 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung Recruiting USA 0
NCT06663098 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). (CARRY-ON) Not yet recruiting ITA 0
NCT02763579 Phase III Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) Completed USA | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | BRA | AUT | AUS 8


Additional content available in CKB BOOST